OBJECTIVE: To determine the associations between the pretreatment characteristics and treatment selection in patients presenting with clinical stage I renal masses. MATERIALS AND METHODS: Using institutional data, patients presenting with clinical stage I (≤ 7 cm) renal tumors that were managed with active surveillance (AS), tumor ablation (ABL), partial nephrectomy (PN), or radical nephrectomy (RN) from 2005 to 2011 were identified. The associations between the pretreatment characteristics and the selected treatment strategy were assessed using multinomial regression models, with RN as the reference group. RESULTS: A total of 969 patients (mean age 61.9 ± 12.8 years) with 1034 clinical stage I lesions (mean tumor size 3.3 ± 1.5 cm) met the inclusion criteria. The patients were initially treated with RN (29.4%), PN (38.8%), ABL (6.1%), and AS (25.7%). Traditionally captured covariates, including older age (PN, odds ratio [OR] 0.96, 95% confidence interval [CI] 0.94-0.99]) and decreasing tumor size (PN, OR 0.2, 95% CI 0.1-0.4; ABL, OR 0.01, 95% CI 0.0-0.1; AS, OR 0.2, 95% CI 0.1-0.3) were associated with alternative treatment types compared with RN. However, the characteristics associated with treatment type that are not included in traditional registry or administrative data included the presence of a solitary kidney (PN, OR 11.9, 95% CI 2.9-48.9; ABL, OR 15.5, 95% CI 2.5-98.1; AS, OR 7.1, 95% CI 1.3-39.3) and high complexity nephrectomy score (PN, OR 0.1, 95% CI 0.1-0.3; ABL, OR 0.1, 95% CI 0.0-0.6; AS, OR 0.1, 95% CI 0.03-0.3). CONCLUSION: Pretreatment characteristics associated with treatment type in our series, including the presence of a solitary kidney and anatomic complexity, are poorly captured using administrative and registry data. Observational studies investigating the variations in practice patterns for stage I renal masses require improved integration of clinical and tumor characteristics to reduce selection biases.
OBJECTIVE: To determine the associations between the pretreatment characteristics and treatment selection in patients presenting with clinical stage I renal masses. MATERIALS AND METHODS: Using institutional data, patients presenting with clinical stage I (≤ 7 cm) renal tumors that were managed with active surveillance (AS), tumor ablation (ABL), partial nephrectomy (PN), or radical nephrectomy (RN) from 2005 to 2011 were identified. The associations between the pretreatment characteristics and the selected treatment strategy were assessed using multinomial regression models, with RN as the reference group. RESULTS: A total of 969 patients (mean age 61.9 ± 12.8 years) with 1034 clinical stage I lesions (mean tumor size 3.3 ± 1.5 cm) met the inclusion criteria. The patients were initially treated with RN (29.4%), PN (38.8%), ABL (6.1%), and AS (25.7%). Traditionally captured covariates, including older age (PN, odds ratio [OR] 0.96, 95% confidence interval [CI] 0.94-0.99]) and decreasing tumor size (PN, OR 0.2, 95% CI 0.1-0.4; ABL, OR 0.01, 95% CI 0.0-0.1; AS, OR 0.2, 95% CI 0.1-0.3) were associated with alternative treatment types compared with RN. However, the characteristics associated with treatment type that are not included in traditional registry or administrative data included the presence of a solitary kidney (PN, OR 11.9, 95% CI 2.9-48.9; ABL, OR 15.5, 95% CI 2.5-98.1; AS, OR 7.1, 95% CI 1.3-39.3) and high complexity nephrectomy score (PN, OR 0.1, 95% CI 0.1-0.3; ABL, OR 0.1, 95% CI 0.0-0.6; AS, OR 0.1, 95% CI 0.03-0.3). CONCLUSION: Pretreatment characteristics associated with treatment type in our series, including the presence of a solitary kidney and anatomic complexity, are poorly captured using administrative and registry data. Observational studies investigating the variations in practice patterns for stage I renal masses require improved integration of clinical and tumor characteristics to reduce selection biases.
Authors: Gregory J Broughton; Peter E Clark; Daniel A Barocas; Michael S Cookson; Joseph A Smith; S Duke Herrell; Sam S Chang Journal: BJU Int Date: 2011-09-21 Impact factor: 5.588
Authors: Simon P Kim; Nilay D Shah; Christopher J Weight; R Houston Thompson; James P Moriarty; Nathan D Shippee; Brian A Costello; Stephen A Boorjian; Bradley C Leibovich Journal: J Urol Date: 2011-09-25 Impact factor: 7.450
Authors: Sanjay G Patel; David F Penson; Baldeep Pabla; Peter E Clark; Michael S Cookson; Sam S Chang; S Duke Herrell; Joseph A Smith; Daniel A Barocas Journal: J Urol Date: 2012-01-15 Impact factor: 7.450
Authors: Bruce L Jacobs; Hung-Jui Tan; Jeffrey S Montgomery; Alon Z Weizer; David P Wood; David C Miller; J Stuart Wolf; Khaled S Hafez Journal: Urology Date: 2012-05 Impact factor: 2.649
Authors: Matthew R Danzig; Peter Chang; Andrew A Wagner; Mohamad E Allaf; James M McKiernan; Phillip M Pierorazio Journal: Curr Urol Rep Date: 2016-01 Impact factor: 3.092
Authors: Reza Mehrazin; Marc C Smaldone; Brian Egleston; Jeffrey J Tomaszewski; Charles W Concodora; Timothy K Ito; Philip H Abbosh; David Y T Chen; Alexander Kutikov; Robert G Uzzo Journal: Urol Oncol Date: 2015-03-14 Impact factor: 3.498
Authors: Marc C Smaldone; Brian Egleston; John M Hollingsworth; Brent K Hollenbeck; David C Miller; Todd M Morgan; Simon P Kim; Aseem Malhotra; Elizabeth Handorf; Yu-Ning Wong; Robert G Uzzo; Alexander Kutikov Journal: Med Care Date: 2017-04 Impact factor: 2.983
Authors: Jeffrey J Tomaszewski; Robert G Uzzo; Neil Kocher; Tianyu Li; Brandon Manley; Reza Mehrazin; Timothy Ito; Philip Abbosh; Rosalia Viterbo; David Y T Chen; Richard E Greenberg; Daniel Canter; Marc C Smaldone; Alexander Kutikov Journal: Urol Oncol Date: 2014-06-07 Impact factor: 3.498
Authors: Claire Kim; Frances C Wright; Nicole J Look Hong; Gary Groot; Lucy Helyer; Pamela Meiers; May Lynn Quan; Robin Urquhart; Rebecca Warburton; Anna R Gagliardi Journal: PLoS One Date: 2018-02-05 Impact factor: 3.240
Authors: Alejandro Cruz; Faith Dickerson; Kathryn R Pulling; Kyle Garcia; Francine C Gachupin; Chiu-Hsieh Hsu; Juan Chipollini; Benjamin R Lee; Ken Batai Journal: Int J Environ Res Public Health Date: 2022-02-12 Impact factor: 3.390